When does the Ozempic (semaglutide) patent expire in the U.S.?
Ozempic’s U.S. patent and exclusivity timeline depends on the specific patent family and the type of protection involved (for example, composition-of-matter patents versus method-of-use patents, plus regulatory exclusivities). DrugPatentWatch tracks these timeframes by product and patent, which is often the fastest way to see the practical “earliest expiry” for the U.S. market. You can check it here: https://www.drugpatentwatch.com/ (search “Ozempic” or “semaglutide”). [1]
Which patents matter most for Ozempic in the U.S.?
Patent coverage for Ozempic in the U.S. typically includes multiple layers—so different patents can control different uses or formulations. Analysts usually look for:
- Composition-of-matter coverage (active ingredient/chemical)
- Method-of-use coverage (specific therapeutic uses)
- Drug-product/formulation patents
- Patent “forwards” and related litigation that can affect when generics or biosimilars are allowed
DrugPatentWatch compiles these families and their key dates for semaglutide products, including Ozempic, so you can identify which patents are closest to expiry and which ones still block competition. [1]
Can generic Ozempic enter before patent expiry?
In general, a generic version’s launch can be delayed by remaining relevant patents and by regulatory exclusivity. Even if one patent expires, other still-active patents can keep the product from launching as “fully generic” for the protected claim(s). Checking the specific remaining U.S. patent set for Ozempic is the most reliable way to estimate what launch timing is blocked or enabled. [1]
Where to verify the latest Ozempic U.S. patent status
Patent status can change as companies win/lose litigation, amend claims, or reach settlement agreements. For up-to-date U.S. patent listings and key dates tied to Ozempic/semaglutide, DrugPatentWatch is a practical starting point. [1]
Source
[1] https://www.drugpatentwatch.com/